# ðŸ’Š Affordable Drug Alternatives: A Comparative Analysis

A summary comparing originator drugs with their lower-cost alternatives for key medical conditions.

---

## ðŸ§  Treatment-Resistant Depression (TRD)

### Esketamine (SpravatoÂ®) vs. Ketamine (IV Infusion)

> **Condition Context:** Treatment-Resistant Depression (TRD) affects patients who have not responded to at least two different antidepressant trials. In the U.S., this represents an estimated **30-40%** of the general MDD population.

#### ðŸ’° Cost Comparison (United States)

| Therapy | Details | Induction Cost (USD) | Estimated Annual Cost (USD)* |
| :--- | :--- | ---: | ---: |
| **Esketamine** | `SpravatoÂ®` nasal spray | ~ $4,720 â€“ $7,080 | **~$20,000 â€“ $30,000** |
| **Ketamine** | Racemic, IV Infusion (Cash-pay) | ~ $2,100 â€“ $6,000 | **~$5,600 â€“ $16,000** |

<br>
*Note: Annual cost is estimated based on a standard treatment protocol, including an initial induction phase followed by a full year of maintenance sessions (approx. 34 sessions/year for SpravatoÂ® and 16 sessions/year for IV Ketamine).

#### ðŸ“Š Head-to-Head Visualization
<p align="center">
Â  <img src="https://github.com/user-attachments/assets/700f5f30-ecaa-4265-910e-afee107310ae" width="600">
</p>

---

## ðŸ’ª Multiple Sclerosis (MS)

### Ocrelizumab (OcrevusÂ®) vs. Rituximab (Biosimilars)

* **Ocrelizumab Brand:** `OcrevusÂ®`
* **Rituximab Biosimilar Brands Include:** `TruximaÂ®`, `RuxienceÂ®`, `Riabniâ„¢`, `HanlikangÂ®`, `DelituoÂ®`

> **Condition Context:** Relapsing-Remitting MS (RRMS) is the most common form, accounting for about **85%** of diagnoses in the US. Primary Progressive MS (PPMS) is less common, affecting **10-15%** of patients.

#### ðŸ’° Annual Cost Comparison by Region (Corrected)

| Region / Payer | Ocrelizumab (OcrevusÂ®) Cost | Rituximab Biosimilar Cost | Notes |
| :--- | :--- | :--- | :--- |
| **United States (Medicare)** | `~$69,949` | `~$11,759` | Based on Average Sales Price (ASP). Significant savings with biosimilar. |
| **United States (Medicaid Net)**| `~$47,671` | `~$5,893` | Net price after mandatory rebates. Highest percentage savings. |
| **Sweden** | `~$12,400` | `~$2,400` | Based on estimated national tender prices. Rituximab is the far cheaper off-label option. |
| **United Kingdom** | `~$12,700` | `~$3,500` | Ocrelizumab cost is the net price after confidential NHS discount. Rituximab cost is for off-label MS use. |
<br>

#### ðŸ“Š Head-to-Head Visualization
<p align="center">
Â  <img width="559" alt="image" src="https://github.com/user-attachments/assets/6033094b-b1fd-4975-be2f-9622752ac757" />
</p>

MS Global Incidence (Cited from https://atlasofms.org/map/global/epidemiology/number-of-people-with-ms#about)
<img width="894" alt="image" src="https://github.com/user-attachments/assets/2e750584-b477-4796-8a7a-c75b6e5b8b3f" />


